Psyence Biomedical Ltd. Common Shares Market Cap ($3.16 Million)
Market Cap & Net Worth: Psyence Biomedical Ltd. Common Shares (PBM)
Psyence Biomedical Ltd. Common Shares market cap. Psyence Biomedical Ltd. Common Shares (NASDAQ:PBM) has a market capitalization of $3.16 Million ($3.16 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29374 globally and #6014 in its home market, demonstrating a -10.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Psyence Biomedical Ltd. Common Shares's stock price $3.29 by its total outstanding shares 1022177 (1.02 Million). Also see Psyence Biomedical Ltd. Common Shares (PBM) cash conversion ratio for how efficiently the company converts equity into cash flow.
Psyence Biomedical Ltd. Common Shares Market Cap History (2021–2026)
Psyence Biomedical Ltd. Common Shares market cap history from 2021 to 2026. Data shows change from $759.73 Million to $3.36 Million (-66.90% CAGR). Check today's stock price for Psyence Biomedical Ltd. Common Shares for real-time trading data and today's change.
Index Memberships
Psyence Biomedical Ltd. Common Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #848 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2712 of 3165 |
Weight: Psyence Biomedical Ltd. Common Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Psyence Biomedical Ltd. Common Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Psyence Biomedical Ltd. Common Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Psyence Biomedical Ltd. Common Shares to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PBM by Market Capitalization
Companies near Psyence Biomedical Ltd. Common Shares in the global market cap rankings as of November 4, 2026. Also see Psyence Biomedical Ltd. Common Shares asset portfolio for a full breakdown of the balance sheet.
Key companies related to Psyence Biomedical Ltd. Common Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Psyence Biomedical Ltd. Common Shares (2021–2026)
Market capitalization of Psyence Biomedical Ltd. Common Shares from 2021 to today. Between 2021 and today, Psyence Biomedical Ltd. Common Shares's market cap moved from $759.73 Million to $ 3.36 Million, with a yearly change of -66.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.36 Million | +336.69% |
| 2025 | $770.11K | -67.24% |
| 2024 | $2.35 Million | -99.67% |
| 2023 | $708.37 Million | -10.12% |
| 2022 | $788.10 Million | +3.73% |
| 2021 | $759.73 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Psyence Biomedical Ltd. Common Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.16 Million USD |
| MoneyControl | $3.16 Million USD |
| MarketWatch | $3.16 Million USD |
| marketcap.company | $3.16 Million USD |
| Reuters | $3.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more